EICHORCondition: Sensorineural Hearing Loss · Sponsor: Otonomy, Inc.
The purpose of this study is to evaluate the safety, tolerability, and exploratory efficacy of OTO-413 administered as an intratympanic injection for the treatment of speech-in-noise hearing impairment.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Colorado Otolaryngology Associates LLC dba Colorado ENT & Allergy | Colorado Springs, Colorado, United States | — |
| Research Centers of America | Hollywood, Florida, United States | — |
| South Florida ENT Associates or Research Centers of America | Miami, Florida, United States | — |
| University of South Florida | Tampa, Florida, United States | — |
| Advanced ENT and Allergy, PLLC | Louisville, Kentucky, United States | — |
| Piedmont Ear, Nose & Throat Associates | Winston-Salem, North Carolina, United States | — |
| JBR Clinical Research | Salt Lake City, Utah, United States | — |
| Eastern Virginia Medical School, Department of Otolaryngology | Norfolk, Virginia, United States | — |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04129775